Shanghai MicroPort Medical (Group) Co., Ltd.   Report issue

For profit Phase 4
Founded: Shanghai China (1998)
Status: No NME R&D (1998)

Organization Overview

First Clinical Trial
2017
NCT03008083
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Shanghai MicroPort Medical (Group) Co., Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 4)

Myocardial Ischemia (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 3